EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

被引：0
|
作者：
Behrens, F. [1 ]
Mease, P. J. [2 ]
Helliwell, P. S. [3 ]
Shawi, M. [4 ]
Noel, W. [5 ]
Chakravarty, S. D. [4 ,6 ]
Kollmeier, A. P. [4 ]
Xu, X. L. [4 ]
Xu, S. [4 ]
Wang, Y. [4 ]
Baraliakos, X. [7 ]
机构：
[1] Goethe Univ, Frankfurt, Germany
[2] Univ Washington, Swedish Med Ctr, Seattle, WA 98195 USA
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Janssen R&D, Township, PA USA
[5] Janssen R&D, Beerse, Belgium
[6] Drexel Univ, Philadelphia, PA 19104 USA
[7] Ruhr Univ Bochum, Bochum, Germany
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2021年 / 39卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P158
引用
收藏
页码：1244 / 1245
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study
    Anders, Hans-Joachim
    Chan, Tak Mao
    Sanchez-Guerrero, Jorge
    Wofsy, David
    Bensley, Karen
    Kim, Lilianne
    Lo, Kim Hung
    Shu, Cathye
    Shao, Jie
    Karyekar, Chetan S.
    Diamond, Betty
    RHEUMATOLOGY, 2024,
  • [32] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Baraliakos, Xenofon
    Ranza, Roberto
    Ostor, Andrew
    Ciccia, Francesco
    Coates, Laura C.
    Rednic, Simona
    Walsh, Jessica A.
    Douglas, Kevin
    Gao, Tianming
    Kato, Koji
    Song, In-Ho
    Ganz, Fabiana
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [33] Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
    Xenofon Baraliakos
    Roberto Ranza
    Andrew Östör
    Francesco Ciccia
    Laura C. Coates
    Simona Rednic
    Jessica A. Walsh
    Kevin Douglas
    Tianming Gao
    Koji Kato
    In-Ho Song
    Fabiana Ganz
    Atul Deodhar
    Arthritis Research & Therapy, 25
  • [34] Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
    Gladman, Dafna D.
    Mease, Philip J.
    Bird, Paul
    Soriano, Enrique R.
    Chakravarty, Soumya D.
    Shawi, May
    Xu, Stephen
    Quinn, Sean T.
    Gong, Cinty
    Leibowitz, Evan
    Poddubnyy, Denis
    Tam, Lai-Shan
    Helliwell, Philip S.
    Kavanaugh, Arthur
    Deodhar, Atul
    Ostergaard, Mikkel
    Baraliakos, Xenofon
    TRIALS, 2022, 23 (01)
  • [35] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
    Ritchlin, Christopher T.
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Rampakakis, Emmanouil
    Chakravarty, Soumya
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [36] Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Mease, Philip
    Helliwell, Philip
    Gladman, Dafna
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya
    Kollmeier, Alexa
    Xu, Lillian
    Sheng, Shihong
    Xu, Stephen
    Shawi, May
    van der Heijde, Desiree
    Deodhar, Atul
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 774 - 774
  • [37] EFFECT OF GUSELKUMAB, A SELECTIVE IL-23P19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
    Mease, P. J.
    Helliwell, P.
    Gladman, D. D.
    Poddubnyy, D.
    Baraliakos, X.
    Chakravarty, S. D.
    Kollmeier, A.
    Xu, X. L.
    Sheng, S.
    Xu, S.
    Shawi, M.
    Van der Heijde, D.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 832 - 833
  • [38] Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials
    Alam, Danesh
    Tirado, Carlos
    Pirner, Mark
    Clinch, Thomas
    JOURNAL OF DRUG ASSESSMENT, 2020, 9 (01) : 13 - 19
  • [39] Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Kavanaugh, Arthur
    van der Heijde, Desiree
    McInnes, Iain B.
    Mease, Philip
    Krueger, Gerald G.
    Gladman, Dafna D.
    Gomez-Reino, Juan
    Papp, Kim
    Baratelle, Anna
    Xu, Weichun
    Mudivarthy, Surekha
    Mack, Michael
    Rahman, Mahboob U.
    Xu, Zhenhua
    Zrubek, Julie
    Beutler, Anna
    ARTHRITIS AND RHEUMATISM, 2012, 64 (08): : 2504 - 2517
  • [40] Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
    Mease, Philip
    Helliwell, Philip
    Gladman, Dafna
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Shawi, May
    Karyekar, Chetan
    Sweet, Kristen
    Deodhar, Atul
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345